{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:20:03Z","timestamp":1790648403825,"version":"4.1.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPAA"],"DOI":"10.2147\/cpaa.s44377","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T23:31:04Z","timestamp":1411947064000},"page":"139","source":"Crossref","is-referenced-by-count":17,"title":["Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens"],"prefix":"10.2147","author":[{"given":"Tetsuya","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,9]]},"container-title":["Clinical Pharmacology: Advances and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=21798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:38:50Z","timestamp":1477867130000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/arbekacin-another-novel-agent-for-treating-infections-due-to-methicill-peer-reviewed-article-CPAA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/cpaa.s44377","relation":{},"ISSN":["1179-1438"],"issn-type":[{"value":"1179-1438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}